Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.53 |
| ▸ | THRB | P10828 | 8/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.38 |
| ▸ | THRA | P10827 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527631 | 1.00 | RORC (0.53) | RORCTHRBP2RX3P2RX2THRA | |
| SCHEMBL24449964 | 0.91 | RORC (0.46) | RORCTHRBP2RX3P2RX2THRA | |
| SCHEMBL30558158 | 0.85 | RORC (0.41) | RORCTHRBP2RX3P2RX2THRA | |
| SCHEMBL24449959 | 0.85 | RORC (0.41) | RORCTHRBP2RX3P2RX2THRA | |
| SCHEMBL24449305 | 0.84 | RORC (0.41) | RORCP2RX3P2RX2MAPTPIK3R1 | |
| SCHEMBL24449957 | 0.83 | RORC (0.43) | RORCTHRBP2RX3P2RX2MAPT | |
| SCHEMBL22959236 | 0.82 | RORC (0.47) | RORCTHRBP2RX3P2RX2MAPT | |
| SCHEMBL22959061 | 0.81 | RORC (0.51) | RORCTHRBTHRAMAPT | |
| SCHEMBL29066174 | 0.78 | RORC (0.67) | RORCTHRBTHRA | |
| SCHEMBL29527415 | 0.78 | RORC (0.67) | RORCTHRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| WO-2021026179-A1 | AGONISTS OF ROR GAMMAt | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | THRA, THRB, TSHR | RORC 283/4885THRB 2/4885P2RX3 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.